-
-
-
-
-
-
-
Guggenheim Downgrades Sionna Therapeutics (SION) to Neutral
-
-
-
-
-
-
-
Sionna CF drug trial fails key endpoint; company halts program
-
-
-
-
-
-
-
Sionna Therapeutics (SION) PT Raised to $55 at Stifel On Optimism about ph2a data
-
-
-
-
-
-
-
SION (SION) Tops Q4 EPS by 25c
-
-
-
-
-
-
-
Raymond James Positive on Sionna Therapeutics (SION): 'continue to like the set-up into initial POC data next year'
-
-
-
-
-
-
-
Sionna Therapeutics (SION) Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model
-
-
-
-
-
-
-
Stifel Starts Sionna Therapeutics (SION) at Buy
-
479,029 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


